welcomeThe King's Thrombosis Centre is a leading multidisciplinary clinical and research group dedicated to the diagnosis and treatment of hypercoagulable conditions. We are a designated Haemophilia Centre and were the first National Venous Thromboembolism (VTE) Exemplar Centre, reflecting our national leadership in the prevention and treatment of VTE. Our clinical trials unit works in partnership with industry to develop new treatments for VTE prevention and treatment.



The FIRST Registry

With the next generation of oral anticoagulants entering clinical practice, the FIRST registry will provide an important data tool to increase knowledge and improve the quality of care of patients with VTE. Read more...

Exemplar Centre Network website


The Exemplar Centre Network website has moved. After being hosted at the King's Thrombosis Centre website since its launch in 2007, the website will now be managed as part of the National VTE prevention Programme and can be accessed by clicking here.

Latest News

  • Anticoagulation news items. Weeks commencing 1st February 2016
    Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial The Lancet Haematology Additional catheter-directed thrombolysis resulted in a persistent and…
  • Anticoagulation news items. Weeks commencing 25th January 2016
    Revised SPC: TachoSil (human fibrinogen and thrombin) sealant matrix electronic Medicines Compendium SPC advises that to prevent development of tissue adhesions (AHs) at undesired sites, tissue areas outside desired application…
  • Anticoagulation news items. Weeks commencing 18th January 2016
    Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial The Lancet Haematology In this phase 2a proof-of concept trial (n=36) patients with livedoid vasculopathy…